EE500 Budget Impact of Subcutaneous Immunoglobulin, Intravenous Immunoglobulin, and Efgartigimod Alfa in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the United States
Abstract
Authors
R Mallick R Carlton J van Stiphout A Hubsch BJ Lahue